AR10523PU-S Epstein Barr Virus mosaic EBNA1

Search for all "Epstein Barr Virus mosaic EBNA1"

Quick Overview

Epstein Barr Virus mosaic EBNA1


Product Description for Epstein Barr Virus mosaic EBNA1

Epstein Barr Virus mosaic EBNA1.
Presentation: Purified

Properties for Epstein Barr Virus mosaic EBNA1

Product Category Proteins & Growth Factors
Quantity 0.1 mg
Presentation Purified
Source E. coli
Shipping to Worldwide
PDF datasheet View Datasheet
Manufacturer OriGene Technologies GmbH
Material safety datasheet MSDS for Proteins (de)

Datasheet Extract

Purity >95% pure as determined by 10% PAGE (coomassie staining).
Purification Method: Sepharose-Derived Purification.
Application Antigen in ELISA and Western blots, excellent antigen for detection of HHV-4 (EBV)- with minimal specificity problems.
Background The Epstein-Barr virus (EBV), also called Human herpes virus 4 (HHV-4), is a virusof the herpes family (which includes Herpes simplex virusand Cytomegalo virus. On infecting the B-lymphocyte, the linear virus genome circularizes and the virus subsequently persists within the cell as an episome. The virus can execute several distinct programs of gene expressionwhich can be broadly categorized as being lytic cycle or latent cycle. The lytic cycleor productive infection results in staged expression of a host of viral proteinswith the ultimate objective of producing infectious virions. Formally, this phase of infection does not inevitably lead to lysis of the host cellas EBV virions are produced by budding from the infected cell. The latent cycle(lysogenic) programs are those that do not result in production of virions. A very limited, distinct set of viral proteins are produced during latent cycle infection. These include Epstein-Barr nuclear antigen(EBNA)-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-leader protein (EBNA-LP) and latent membrane proteins(LMP)-1, LMP-2A and LMP-2B and the Epstein-Barr encoded RNAs(EBERs).  
Concentration 1.0 mg/ml
E.coli derived recombinant. The mosaic protein contains the HHV-4 EBNA regions.
Specificity: Immunoreactive with sera of EBV-infected individuals.
Buffer System:
50mM Tris-HCl, 10mM Glutation, 60mM NaCl, 0.5% Sarcosyl
>95% pure as determined by 10% PAGE (coomassie staining).
Purification Method: Sepharose-Derived Purification.
  • LinkedIn